Lamivudine and zidovudine
Generic name: Lamivudine And Zidovudine
Brand names: Combivir
Dosage form: oral tablet (150 mg-300 mg)
Drug class:
Antiviral combinations
Usage of Lamivudine and zidovudine
Lamivudine and zidovudine are antiviral medications that prevent human immunodeficiency virus (HIV) from multiplying in your body.
Lamivudine and zidovudine is a combination medicine used to treat HIV, the virus that can cause acquired immunodeficiency syndrome (AIDS). Lamivudine and zidovudine is not a cure for HIV or AIDS.
Lamivudine and zidovudine may also be used for purposes not listed in this medication guide.
Lamivudine and zidovudine side effects
Get emergency medical help if you have signs of an allergic Reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Mild symptoms of lactic acidosis may worsen over time, and this condition can be fatal. Get emergency medical help if you have: unusual muscle pain, trouble breathing, stomach pain, vomiting, irregular heart rate, dizziness, feeling cold, or feeling very weak or tired.
Lamivudine and zidovudine may cause serious side effects. Call your doctor at once if you have:
Lamivudine and zidovudine affects your immune system, which may cause certain side effects (even weeks or months after you've taken lamivudine and zidovudine). Tell your doctor if you have:
Common side effects of lamivudine and zidovudine may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Lamivudine and zidovudine
You should not take lamivudine and zidovudine if you are allergic to lamivudine. Do not take Combivir with any other medicine that contains lamivudine, zidovudine, or Emtricitabine. This includes Atripla, Biktarvy, Cimduo, Combivir, Complera, Descovy, Emtriva, Epzicom, Genvoya, Odefsey, Retrovir, Stribild, Symfi, Triumeq, Trizivir, and Truvada.
Lamivudine and zidovudine can also cause severe or fatal liver problems. Tell your doctor if you have liver disease, especially hepatitis B.
Lamivudine and zidovudine should not be used to treat HIV in adolescents weighing less than 66 pounds.
Tell your doctor if you have ever had:
You may develop lactic acidosis, a dangerous build-up of lactic acid in your blood. This may be more likely if you have other medical conditions, if you've taken HIV medication for a long time, or if you are a woman. Ask your doctor about your risk.
Tell your doctor if you are pregnant, and use your medications properly to control your infection. HIV can be passed to your baby if the virus is not controlled during pregnancy. Your name may be listed on a registry to track any effects of antiviral medicine on the baby.
Women with HIV or AIDS should not breast-feed a baby. Even if your baby is born without HIV, the virus may be passed to the baby in your breast milk.
Relate drugs
- AccessPak for HIV PEP Basic
- AccessPak for HIV PEP Expanded with Kaletra
- AccessPak for HIV PEP Expanded with Viracept
- Atazanavir and cobicistat
- Atripla
- Cobicistat and darunavir
- Cobicistat, darunavir, emtricitabine, and tenofovir
- Cobicistat, elvitegravir, emtricitabine, and tenofovir
- Combivir
- Complera
- Abacavir and lamivudine
- Abacavir, dolutegravir, and lamivudine
- Abacavir, lamivudine, and zidovudine
- Bictegravir, emtricitabine, and tenofovir
- Bictegravir, emtricitabine, and tenofovir alafenamide
- Biktarvy
- Cabenuva
- Cabotegravir and rilpivirine
- Casirivimab and imdevimab
- Cilgavimab and tixagevimab
- Cimduo
- Darunavir and cobicistat
- Darunavir, cobicistat, emtricitabine, and tenofovir alafenamide
- Dasabuvir, ombitasvir, paritaprevir, and ritonavir
- Delstrigo
- Descovy
- Descovy Blister Pack
- Dolutegravir and lamivudine
- Dolutegravir and rilpivirine
- Doravirine, lamivudine, and tenofovir
- Dovato
- Efavirenz, emtricitabine, and tenofovir
- Efavirenz, lamivudine, and tenofovir
- Elbasvir and grazoprevir
- Elvitegravir, cobicistat, emtricitabine, and tenofovir
- Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide
- Emtricitabine and tenofovir
- Emtricitabine and tenofovir alafenamide
- Emtricitabine, lopinavir, ritonavir, and tenofovir
- Emtricitabine, nelfinavir, and tenofovir
- Emtricitabine, rilpivirine, and tenofovir
- Emtricitabine, rilpivirine, and tenofovir alafenamide
- Epclusa
- Epzicom
- Evotaz
- Evusheld
- Genvoya
- Glecaprevir and pibrentasvir
- Harvoni
- Juluca
- Lamivudine and tenofovir
- Lamivudine and zidovudine
- Ledipasvir and sofosbuvir
- Mavyret
- Nirmatrelvir and ritonavir
- Odefsey
- Ombitasvir, paritaprevir, and ritonavir
- Ombitasvir, paritaprevir, ritonavir and dasabuvir
- Paxlovid
- Prezcobix
- Regen-Cov
- Sofosbuvir and Velpatasvir
- Sofosbuvir, velpatasvir, and voxilaprevir
- Stribild
- Symfi
- Symfi Lo
- Symtuza
- Technivie
- Temixys
- Triumeq
- Triumeq PD
- Trizivir
- Truvada
- Viekira
- Viekira Pak
- Viekira XR
- Vosevi
- Zepatier
How to use Lamivudine and zidovudine
Usual Adult Dose for HIV Infection:
1 tablet orally twice a dayUse: In combination with other antiretrovirals, for the treatment of HIV-1 infection
Usual Adult Dose for Nonoccupational Exposure:
US CDC recommendations: 1 tablet orally every twice a dayDuration of therapy: 28 daysComments:-Recommended as part of a preferred NNRTI-based or protease inhibitor-based regimen for nonoccupational postexposure prophylaxis of HIV infection; also recommended as part of alternative regimens (NNRTI-based, protease inhibitor-based, or triple NRTI)-Prophylaxis should be started as soon as possible, within 72 hours of exposure.-Current guidelines should be consulted for additional information.
Usual Adult Dose for Occupational Exposure:
US Public Health Service working group recommendations: 1 tablet orally twice a dayDuration of therapy: 28 days, if toleratedComments:-Recommended as part of alternative regimens for HIV postexposure prophylaxis-Prophylaxis should be started as soon as possible, preferably within hours after exposure.-The optimal duration of prophylaxis is unknown and may differ based on the institution protocol.-Current guidelines should be consulted for additional information.
Usual Pediatric Dose for HIV Infection:
At least 30 kg: 1 tablet orally twice a dayComments:-Use of the individual components is recommended for patients less than 30 kg; the manufacturer product information for lamivudine and zidovudine should be consulted.Use: In combination with other antiretrovirals, for the treatment of HIV-1 infection
Warnings
Do not take this medicine if you have ever had an allergic reaction to any medicine that contains lamivudine or zidovudine.
Zidovudine can weaken your immune system and cause signs of infection (fever, mouth sores, skin sores, flu symptoms, pale skin). Your blood will need to be tested often. Long-term use of zidovudine can cause muscle weakness, or loss of muscle tissue similar to "wasting syndrome" caused by HIV.
You may develop lactic acidosis, a dangerous build-up of lactic acid in your blood. Call your doctor or get emergency medical help if you have unusual muscle pain, trouble breathing, stomach pain, dizziness, feeling cold, or feeling very weak or tired.
If you've ever had hepatitis B, it may become active or get worse after you stop using this medicine. You may need frequent liver function tests for several months.
What other drugs will affect Lamivudine and zidovudine
Tell your doctor about all your other medicines, especially:
This list is not complete. Other drugs may affect lamivudine and zidovudine, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions